Page last updated: 2024-08-25

ljc 10627 and Central Nervous System Diseases

ljc 10627 has been researched along with Central Nervous System Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hikida, M; Inomata, N; Masukawa, Y; Nishiki, K	1

Other Studies

1 other study(ies) available for ljc 10627 and Central Nervous System Diseases

Article	Year
Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:2 Topics: Animals; Behavior, Animal; Binding, Competitive; Central Nervous System Diseases; Diazepam; GABA-A Receptor Antagonists; In Vitro Techniques; Male; Muscimol; Rats; Rats, Sprague-Dawley; Receptors, Glycine; Receptors, Neurotransmitter; Seizures; Strychnine; Synaptic Membranes; Thienamycins	1993

Article

Year

Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats.

Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:2

Topics: Animals; Behavior, Animal; Binding, Competitive; Central Nervous System Diseases; Diazepam; GABA-A Receptor Antagonists; In Vitro Techniques; Male; Muscimol; Rats; Rats, Sprague-Dawley; Receptors, Glycine; Receptors, Neurotransmitter; Seizures; Strychnine; Synaptic Membranes; Thienamycins

1993